Natco Pharma Limited (NSE: NATCO PHARM) announces FDA approval for Eribulin Mesylate Injection, a bioequivalent to Halaven®.
Lupin Limited (LUPIN) and Natco Pharma receive FDA approval for Eribulin Mesylate Injection, a bioequivalent to Halaven®.
Shilpa Medicare Limited (NSE: SHILPAMED) acquires 30.4% stake in Gate2Brain to advance brain cancer therapy.
Alkem Laboratories Limited (NSE: ALKEM) becomes the first in India to launch semaglutide in single-shot pre-filled syringes starting at INR 350.
Wanbury Limited (WANBURY) announced FY26 results with 117% YoY PAT growth, EPS doubling, and new API launches.
Marksans Pharma Limited (NSE: MARKSANS) to acquire 100% of QliniQ B.V., enhancing its presence in European markets.
Wockhardt Limited (WOCKPHARMA) receives U.S. FDA approval for ZAYNICH™, a novel antibiotic for treating complicated urinary tract infections.
Anlon Healthcare Limited (AHCL) reports 43% revenue growth and 48% EBITDA surge in Q4 FY26, driven by strategic acquisitions and robust R&D.
Lupin Limited (NSE: LUPIN) secures U.S. FDA approval for Sodium Sulfate, Magnesium Sulfate, and Potassium Chloride Tablets, marking a significant milestone.
Max India Limited (MAXIND) reports Q4FY26 revenue up 44%, strong growth in residences, services, and AGEasy.